查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602811

抗生素市场：给药途径、按药物类别、分销管道 - 2025-2030 年全球预测

Antibacterial Drugs Market by Routes of Administration (Enteral, Parenteral), Drug Class (Aminoglycoside, B - Lactams, Macrolides), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年抗生素市值为376.3亿美元，预计2024年将达到391.5亿美元，复合年增长率为4.12%，到2030年将达到499.4亿美元。

抗生素市场包括多种旨在对抗细菌感染的治疗药物。这些药物在医疗保健和农业中发挥重要作用，可对抗从轻微到危及生命的各种疾病。细菌感染疾病的持续威胁强调了对抗菌剂的需求，而抗生素抗药性菌株数量的增加加剧了这种威胁，特别是在治疗肺炎、结核病和尿道感染的应用。最终使用领域主要包括医院、诊所和门诊病人，但兽医和农业也是重要的应用领域。促进市场成长的主要因素是感染疾病率的增加，以及人们对感染疾病认识的提高和诊断技术的进步。此外，细菌抗药性模式的持续演变刺激了新药类别的持续创新和研发工作，使得公司越来越渴望开发具有更好功效和安全性的新型抗菌剂，投资药物和製剂开发的潜在机会正在扩大。然而，新兴市场面临重大限制，包括研发成本高、时间长、监管障碍以及限制新药采用的潜在副作用。此外，现有抗生素的广泛滥用和过度使用正在加剧抗药性问题，并对产业成长构成挑战。为了克服这些限制，需要在该领域进行创新，特别是在开发窄频谱抗生素、噬菌体疗法和益生菌等替代疗法以及指导准确抗生素使用的快速诊断方面。公司还应专注于协作研究和伙伴关係关係，以缩短产品开发时间并提高市场渗透率。市场的动态性质需要不断适应技术和监管变化，而进步和不断发展的细菌抗药性对于公司确保可持续成长并为改善全球健康做出贡献至关重要。

主要市场统计
基准年[2023] 376.3亿美元
预测年份 [2024] 391.5亿美元
预测年份 [2030] 499.4亿美元
复合年增长率（%） 4.12%

市场动态：揭示快速发展的抗生素市场的关键市场洞察

供需的动态交互作用正在改变抗生素市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 感染疾病流行的蔓延
    • 新抗生素的核准和上市数量不断增加
    • 学名药的普及
  • 市场限制因素
    • 抗菌药物专利到期
  • 市场机会
    • 开发具有更高功效和更少副作用的新化合物
    • 新兴国家抗生素的采用
  • 市场挑战
    • 多重抗药性细菌的存在

波特五力：驾驭抗生素市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对抗菌药物市场的影响

外部宏观环境因素在塑造抗生素市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解抗菌药物市场竞争状况

抗生素市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵抗生素市场供应商的绩效评估

FPNV定位矩阵是评估抗生素市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製抗生素市场的成功之路

抗生素市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病的传播
      • 增加新抗生素的核准和上市
      • 学名药的普及
    • 抑制因素
      • 抗菌药物专利到期
    • 机会
      • 创新新化合物，提高疗效并减少副作用
      • 新兴国家抗生素的采用
    • 任务
      • 存在多重抗药性菌株
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依给药途径分類的抗生素市场

  • 肠内的
  • 胃肠外的

第七章依药物类别分類的抗生素市场

  • Aminoglycosides
  • B-内酰胺
  • 大环内酯
  • 苯尼考
  • 奎诺酮
  • 磺胺类药物
  • 四环霉素

第八章抗生素市场：按分销管道

  • 药局和药房
  • 医院药房
  • 网路药房

第九章美洲抗生素市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区抗生素市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲抗生素市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Allecra Therapeutics GmbH
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Debiopharm Group
  • Eli Lilly and Company
  • Entasis Therapeutics by Innoviva, Inc.
  • GlaxoSmithKline PLC
  • Iterum Therapeutics PLC
  • Johnson & Johnson Services Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Melinta Therapeutics LLC
  • Merck & Co., Inc.
  • Sanofi-Aventis Groupe SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4358BACA8012

The Antibacterial Drugs Market was valued at USD 37.63 billion in 2023, expected to reach USD 39.15 billion in 2024, and is projected to grow at a CAGR of 4.12%, to USD 49.94 billion by 2030.

The market for antibacterial drugs encompasses a wide array of therapeutic agents designed to combat bacterial infections. These drugs play a critical role in both healthcare and agricultural sectors, countering diseases that range from mild to life-threatening. The necessity of antibacterial drugs is underscored by the persistent threat of bacterial infections, heightened by the rise of antibiotic-resistant strains, which significantly underscores their application in treating conditions such as pneumonia, tuberculosis, and urinary tract infections, among others. End-use sectors predominantly include hospitals, clinics, and outpatient facilities, while the veterinary industry and agriculture also represent significant application areas. A key influencer of market growth is the increasing prevalence of infectious diseases, coupled with heightened awareness and diagnostic advancements. Moreover, the constant evolution of bacterial resistance patterns stimulates ongoing innovation and R&D efforts into new drug classes, thus opening potential opportunities for companies to invest in the development of novel antibacterial agents or formulations with better efficacy and safety profiles. However, the market faces substantial limitations, notably the high costs and lengthy timelines associated with research and development, regulatory hurdles, and the potential for adverse effects, which restrict the proliferation of new drugs. Furthermore, the widespread misuse or overuse of existing antibiotics exacerbates resistance issues, posing a challenge to industry growth. To overcome these limitations, the sector is poised for innovation, especially in developing narrow-spectrum antibiotics, alternative therapies such as phage therapy and probiotics, and rapid diagnostics that guide precise antimicrobial use. Businesses should also focus on collaborations and partnerships to expedite product development timelines and enhance market penetration. The market's dynamic nature requires continuous adaptation to technological and regulatory changes, emphasizing the importance for companies to stay abreast of advancements and evolving bacterial resistance trends to secure sustained growth and contribute to global health improvements.

KEY MARKET STATISTICS
Base Year [2023] USD 37.63 billion
Estimated Year [2024] USD 39.15 billion
Forecast Year [2030] USD 49.94 billion
CAGR (%) 4.12%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibacterial Drugs Market

The Antibacterial Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of infectious diseases
    • Increasing approval and launch of new antibacterial drugs
    • Widespread of the generic drugs
  • Market Restraints
    • Patent expiry of the antibacterial drug
  • Market Opportunities
    • Innovation in some novel compounds with improved efficacy, and fewer side effects associated with the drugs
    • Adoption of antibacterial drugs in emerging countries
  • Market Challenges
    • Presence of multi-drug resistant bacterial strains

Porter's Five Forces: A Strategic Tool for Navigating the Antibacterial Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibacterial Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibacterial Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibacterial Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibacterial Drugs Market

A detailed market share analysis in the Antibacterial Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibacterial Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibacterial Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibacterial Drugs Market

A strategic analysis of the Antibacterial Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibacterial Drugs Market, highlighting leading vendors and their innovative profiles. These include Allecra Therapeutics GmbH, Allergan PLC, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Debiopharm Group, Eli Lilly and Company, Entasis Therapeutics by Innoviva, Inc., GlaxoSmithKline PLC, Iterum Therapeutics PLC, Johnson & Johnson Services Inc., Kyorin Pharmaceutical Co., Ltd., Melinta Therapeutics LLC, Merck & Co., Inc., Sanofi-Aventis Groupe S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibacterial Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Routes of Administration, market is studied across Enteral and Parenteral.
  • Based on Drug Class, market is studied across Aminoglycoside, B - Lactams, Macrolides, Phenicols, Quinolones, Sulfonamide, and Tetracycline.
  • Based on Distribution Channel, market is studied across Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of infectious diseases
      • 5.1.1.2. Increasing approval and launch of new antibacterial drugs
      • 5.1.1.3. Widespread of the generic drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Patent expiry of the antibacterial drug
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovation in some novel compounds with improved efficacy, and fewer side effects associated with the drugs
      • 5.1.3.2. Adoption of antibacterial drugs in emerging countries
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of multi-drug resistant bacterial strains
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibacterial Drugs Market, by Routes of Administration

  • 6.1. Introduction
  • 6.2. Enteral
  • 6.3. Parenteral

7. Antibacterial Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Aminoglycoside
  • 7.3. B - Lactams
  • 7.4. Macrolides
  • 7.5. Phenicols
  • 7.6. Quinolones
  • 7.7. Sulfonamide
  • 7.8. Tetracycline

8. Antibacterial Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Drug Stores & Retail Pharmacies
  • 8.3. Hospital Pharmacies
  • 8.4. Online Pharmacies

9. Americas Antibacterial Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibacterial Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibacterial Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Allecra Therapeutics GmbH
  • 2. Allergan PLC
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Bristol-Myers Squibb Company
  • 6. Debiopharm Group
  • 7. Eli Lilly and Company
  • 8. Entasis Therapeutics by Innoviva, Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Iterum Therapeutics PLC
  • 11. Johnson & Johnson Services Inc.
  • 12. Kyorin Pharmaceutical Co., Ltd.
  • 13. Melinta Therapeutics LLC
  • 14. Merck & Co., Inc.
  • 15. Sanofi-Aventis Groupe S.A.
  • 16. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTIBACTERIAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBACTERIAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBACTERIAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBACTERIAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY B - LACTAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PHENICOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG STORES & RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023